Skip to content

New fixed-dose combination pills measure up to Atripla - corrected version*

Long-acting fusion inhibitor albuvirtide looks promising in early studies

Dolutegravir matches raltegravir for people starting treatment

Francois Raffi. Image ©Liz Highleyman / hivandhepatitis.com

High levels of adherence reached in two PrEP studies, but resistance cases show need for rigorous testing before prescribing

HIV treatment breaks lead to drug resistance in the female genital tract

Superinfection: second HIV infections happen as often as first ones

Second-line treatment failure most often due to poor adherence in low and middle-income countries

Drug combinations pairing AZT and efavirenz have highest resistance risk

'High viral load' should mean over half a million copies, not over 100,000, Rome study suggests